Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients
- Status
- UNKNOWN
- Phase
- PHASE3
Clinical Trials Related to Mantle Cell Lymphoma
Related studies linked through entity extraction aliases.
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
- Status
- COMPLETED
- Phase
- PHASE1
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib
- Status
- UNKNOWN
- Phase
- N/A
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
- Status
- COMPLETED
- Phase
- PHASE1
CART-19 Immunotherapy in Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Ublituximab + Ibrutinib in Select B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
- Status
- COMPLETED
- Phase
- PHASE3
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- Status
- RECRUITING
- Phase
- PHASE3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE2
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of LY2835219 for Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
- Status
- TERMINATED
- Phase
- PHASE1
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2